European Drug Review’s June Meeting Opens the Door With One Hand and Hits the Brakes With the Other

The monthly meeting of Europe’s medicines review body often reads like a health check for medical innovation: some technologies finally cross the evidence threshold, while others are forced to stop just before reaching the market. At the June 22 to 25 meeting of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the committee issued positive opinions for six medicines, while also issuing negative opinions for a tumor-infiltrating lymphocyte cell therapy, a fecal microbiota product, and a drug for transplant complications. Together, the decisions reflected regulators’ dual stance toward new mechanisms and highly complex products: they welcome treatment options for unmet needs, but the chain of evidence must hold up.

The positive opinions this time included Onswik for adults with type 2 diabetes, the influenza vaccine Aujemflu for adults aged 50 and older, the Parkinson’s disease drug Hopledo, and Daybu for Rett syndrome, which received support after re-examination. A positive CHMP opinion is not the same as formal approval by the European Commission, but it is usually the most critical step in the EU’s centralized review procedure. Only after a marketing authorization is granted can a product be sold in the EU market for its approved indication.

Onswik is one of the products from this meeting with more direct relevance to everyday clinical practice. EMA’s medicine page shows that the drug was submitted by Eli Lilly Nederland B.V.; its active substance is insulin efsitora alfa, a long-acting basal insulin analogue intended for adults with type 2 diabetes. EMA said its blood-glucose-lowering effect comes from the QWINT 1 to 4 phase 3, randomized, active-controlled trials. In these studies, once-weekly insulin efsitora alfa was comparable with once-daily basal insulin in reducing glycated hemoglobin. That makes its significance not only a new molecule, but also the possibility of changing the frequency and burden of basal insulin use for some patients.

Convenience, however, does not mean risk disappears. EMA listed hypoglycemia as the most common side effect of Onswik, which is also the core safety issue that insulin therapy cannot avoid. For clinicians and patients, if once-weekly dosing is formally launched, the real tests will include dose adjustment, management of missed or delayed doses, and blood glucose fluctuations in real-world patients with different lifestyles. The publicly available summaries support comparability of efficacy, but they are not enough to replace individualized medical judgment.

In sharp contrast to the approval recommendations was the negative opinion for Tacquell. Tacquell, submitted by the Netherlands Cancer Institute, is an autologous, melanoma-derived tumor-infiltrating lymphocyte advanced therapy medicinal product. Its target population is adults with unresectable advanced melanoma who had previously received PD-1 inhibitor treatment. From the perspective of medical need, this is a highly urgent area; but EMA said the main efficacy and safety data were unreliable, citing serious GCP compliance problems in the main study, along with concerns about study design and analysis.

EMA’s concerns about Tacquell also extended to the completeness of safety data, quality control, product comparability, and insufficient documentation of GMP compliance at manufacturing and quality-control sites. These reasons show that review of cell therapies does not look only at tumor response signals. It also has to confirm how each batch of personalized product is manufactured consistently, how it is tracked, and whether the clinical data are sufficient to support the benefit-risk assessment. For advanced therapies, process and evidence are often not supporting actors before launch, but part of whether the product itself can be trusted.

At the same meeting, Xervyteg and narsoplimab also received negative opinions. The former is an allogeneic fecal microbiota product intended for acute graft-versus-host disease; the latter targets hematopoietic stem cell transplant-associated thrombotic microangiopathy. The public summaries did not provide full details sufficient to break down every reason for each rejection, so it would be inappropriate to reduce the three negative opinions to the same cause of failure. But they fall within a shared trend: when therapeutic products involve living cells, microbial communities, or high-risk transplant complications, regulators require more than biological plausibility. They also require reproducible clinical benefit, clear safety boundaries, and an auditable manufacturing system.

This CHMP meeting therefore was less a simple story of “six new medicines moving forward” than a fresh drawing of boundaries in European medicines review. New options are emerging for chronic disease, vaccines, and neurological disorders. At the same time, cell therapies and microbiome products that represent the next generation of medical imagination are being required to prove themselves with stronger data and quality. Innovation is still moving forward, but on the road to medicines reaching the market, speed ultimately has to yield to verifiable evidence.